Research Highlight
The first step on earth: A small step for a trial, a giant leap for mankind
Abstract
Gastric cancer is the second leading cause of cancer-related
deaths worldwide (1). The 5-year survival rate is about 75% in
resected patients with the early stage of the disease. However, the
prognosis worsens with lymph node involvement, which predicts
an increase in the probability of loco-regional and distant
recurrences. As a result, there is a great interest in adjuvant
therapies for resected gastric cancer patients over the last
40 years.
deaths worldwide (1). The 5-year survival rate is about 75% in
resected patients with the early stage of the disease. However, the
prognosis worsens with lymph node involvement, which predicts
an increase in the probability of loco-regional and distant
recurrences. As a result, there is a great interest in adjuvant
therapies for resected gastric cancer patients over the last
40 years.
